ALL - Novel subgroups and agents
LINKS TO ABSTRACTS:
The study authors conclude that their results demonstrate that loss of IKZF1 confers resistance to AraC, both in experimental models and in patient-derived cells. They are currently performing CRISPR/CAS9 based reverse genetics screens to identify genes/pathways that enhance response to AraC or other antimetabolites. They expect that their approach will allow them to identify (hematopoietic cell-specific) pathways that can be targeted to sensitize responses to AraC in IKZF1 deleted ALL and possibly AML. Finally: Preclinical validations of these findings, using representative PDX models, will guide the development of more effective antimetabolite therapies for this high-risk patient group.
Presentation ID p402-2
Presenter: Anthony Moorman, Newcastle upon Tyne, United Kingdom
The study authors conclude that the UKALL-HeH profile defines two distinct HeH risk groups. Patients with a UKALL-HeH GR profile have an excellent outcome and represent a low-risk subgroup of HeH which could be considered for treatment de-escalation.
Presentation ID p402-3
Presenter: Sabina Chiaretti, Rome, Italy
The study authors conclude that in their updated analysis of the D-ALBA trial, they confirm the very favorable outcome previously reported, as well as the deleterious prognostic impact of the IKZF1-plus genotype and the low transplant-related mortality rate. Among the few relapses, they observed a rather high incidence of CNS involvement. In the upcoming trial for newly diagnosed adult Ph+ ALL, CNS prophylaxis will be increased.
Presentation ID p402-4
Presenter: Nicholas Short, United States
The study authors conclude that the chemotherapy-free combination of ponatinib and blinatumomab shows encouraging safety and efficacy in Ph+ ALL, with high rates of CMR and durable remissions, particularly when used in the frontline setting. All ND patients remain in remission without HSCT, suggesting that this regimen may obviate the need for HSCT in this setting.
Presentation ID p402-5
Presenter: Renato Bassan, Italy
The study authors conclude that their preliminary analysis highlights the efficacy of blinatumomab added to chemotherapy in increasing MRD negativity (<10-4) in CD19+ B-lineage Ph-ALL, with the primary study endpoint fully achieved. This effect appears to translate into a lower early relapse rate and appears detectable in all-risk subsets.